Overview

Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers

Status:
COMPLETED
Trial end date:
2024-06-18
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the effect of the interaction of Erythromycin (CYP3A4/5 moderate inhibitor) on the pharmacokinetic of CHF6001 (CYP3A4/5 substrate) in Healthy Volunteers.
Phase:
PHASE1
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Treatments:
Erythromycin